The support of endocrinologists specialized in the management of pharmacological treatment of obesity should be requested, as emerging evidence shows the benefits of glucagon-like peptide-1 receptor agonist for managing insulin resistance associated with polycystic ovary syndrome. This evidence concerns the gene GLP1R and polycystic ovary syndrome.